Table of Contents:

1 Report Prologue
2 Introduction
2.1 Definition
2.2 Scope of the Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.4.3 Market Structure
3 Research Methodology
3.1 Primary Research Methodology
3.2 Secondary Research Methodology
3.3 Market Size Estimation
3.4 Forecast Model
4 Market Dynamics
4.1 Drivers
4.1.1 Rising Cardiovascular Disorders
4.1.2 Increasing Geriatric Population
4.2 Restraints
4.2.1 High Bleeding Complications
4.3 Opportunities
4.3.1 Exploring New Applications
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunities
5.6 Macroeconomic Indicators
5.7 Pipeline Analysis
6 The Global Ticagrelor Market, by Dosage (Mg)
6.1 Introduction
6.2 90 MG
6.3 60 MG
7 The Global Ticagrelor Market, by Route of Administration
7.1 Introduction
7.2 Oral
7.3 Nasogastric Tube
8 The Global Ticagrelor Market, by Application
8.1 Introduction
8.2 Acute Coronary Syndrome
8.3 Heart Surgeries
8.3.1 Angioplasty
8.3.2 Stent Placement
8.3.3 Coronary Artery Bypass Graft
9 The Global Ticagrelor Market, by End-User
9.1 Introduction
9.2 Hospitals and Clinics
9.3 Ambulatory Centers
10 The Global Ticagrelor Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 U.K.
10.3.1.3 France
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 Rest of the World
10.5.1 Middle East
10.5.2 Africa
10.5.3 Other Countries
11 Company Landscape
11.1 Introduction
12 Company Profiles
12.1 AstraZeneca, PLC
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products Offering
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategy
13 Appendix
13.1 Discussion Blue Print
13.2 References